argenx Presents Interim Results in Myasthenia Gravis Trial

 

• Interim data suggest long-term treatment with VYVGART provides improvementin generalized myasthenia gravis (gMG) disease scores that remainsconsistent over multiple treatment cycles
• Long-term safety profile of VYVGART treatment consistent with Phase 3 ADAPT study
• VYVGARTis the first-and-only approved neonatal Fc receptor (FcRn) blocker

https://www.biospace.com/article/releases/argenx-presents-interim-results-from-adapt-open-label-extension-study-evaluating-vyvgart-efgartigimod-alfa-fcab-in-generalized-myasthenia-gravis-at-2022-aan-annual-meeting/